Table 4. Comparison of reasons given for unwillingness to enroll in RCT, by disclosure arm.
| Standard disclosure (n = 91)a |
Enhanced disclosure (n = 130)a |
|
|---|---|---|
| n (%) | n (%) | |
| Personal experience with current treatment (e.g. inability to be without current medications, desire to remain with current treatment regimens) | 6 (6.6) | 10 (7.7) |
| Direct benefit to self (e.g. higher odds of efficacy with psychiatric treatment, concerns over use of placebo in RCT, side-effects of investigational drug, and overall deterioration of condition) | 49 (53.8) | 74 (56.9) |
| Anti-drug company | 3 (3.3) | 2 (1.5) |
| Anti-medications for depression (e.g. lack of confidence in drugs for treating depression, preference for psychotherapy, preference for both drugs and therapy in combination) | 16 (17.6) | 10 (7.7) |
| Acknowledges importance and value of research | 4 (4.4) | 14 (10.8) |
| Acknowledges higher cost of individual psychiatric treatment | 4 (4.4) | 4 (3.1) |
| Other | 5 (5.5) | 10 (7.7) |
| No response | 4 (4.4) | 6 (4.6) |
a
The number of coded comments, not participants. The denominator for percentages in this table is the number of coded comments from those who expressed preference for individualised treatment in each disclosure arm.